- Strong results for EPS: (34c none-GAAP, 26c GAAP) - Revenues beating estimates by 1m. - Margins excluding the amortization of FISH are very healthy at 69.9%, in light of the fact that FIHS presented 9.5% of revenues this quarter, this means HIFU & ECLIA margins were excellent. - Company mentioned that they will likely raise guidance in November due to the strong ECLIA & FISH results. - R&D was much higher than expected due to the MOH study, but most importantly due to the development of �new products�.
I consider the quarter excellent in terms of ECLIA & FISH, and decent in regards to HIFU, which was exactly what the street is expecting, and still higher than the company guidance of 15% growth.
The company is certainly moving in the right path, and they executing on their business plan, the CC should shade more light on the quarter and future developments.
The street reaction will be interesting, if the market decides to focus on the excellent performance in ECLIA & FISH, the stock will fly, however if they decide to focus on slower HIFU growth and lower margins due to the FISH introduction, the stock will stagnate.